Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

rter of 2009, a 13 percent decrease versus the second quarter of 2008 primarily due to the impact of foreign exchange and the company's Productivity Transformation Program (PTP).

Research and development spending for the 2009 second quarter totaled $863 million, a 5 percent decrease, primarily due to the impact of foreign exchange.

Recent Developments

In addition to the regulatory and pipeline advances discussed above, the company also offered the following summary of recent significant developments that have previously been announced, including:

  • Presented Phase II results of the HCV SPRINT-1 study showing that boceprevir, an oral hepatitis C protease inhibitor, in combination with peginterferon alfa-2b and ribavirin significantly increased sustained virologic response compared to current standard of care. (Announced April 23)
  • Announced changes to the company's global collaboration with Novartis for the development and commercialization of fixed-dose combination therapies for the treatment of asthma and chronic obstructive pulmonary disease. (Announced May 19)
  • Reported that Johnson & Johnson, as a result of the proposed merger between Schering-Plough and Merck, has initiated arbitration proceedings relating to Schering-Plough's rights to REMICADE and SIMPONI. (Announced May 27)
  • Announced that the EMEA had accepted for review the Marketing Authorization Application for SYCREST (asenapine) sublingual tablets for the treatment of schizophrenia and manic episodes associated with bipolar I disorder. (Announced June 2)
  • Reported findings from extensions of two Phase III studies showing that subcutaneous injections of SIMPONI every four weeks provided persistent improvements in the signs and symptoms in patients with psoriatic arthritis and ankylosing spondylitis. Separately, a new analysis was reported sho
    '/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... year, Formedix celebrated its partnership with ... management solutions for clinical trials. The company launched its ... capture (EDC) and clinical data management. Formedix, a renowned ... TrialMaster to its Transform for EDC product line. This ... is being released this week, in response to market ...
(Date:7/23/2014)... , July 23, 2014 ... company of Trendlines Agtech , announced it ... Israel,s leading agricultural thermoplastics applications ... Valentis,s technology combines nanocrystalline cellulose (NCC), a ... with additional nanoparticles to produce highly improved polymeric ...
(Date:7/23/2014)... July 23, 2014 Shire ... the global specialty biopharmaceutical company, and ArmaGen, a ... worldwide licensing and collaboration agreement for AGT-182, an ... treatment of both the central nervous system (CNS) ... (MPS II). This collaboration strengthens Shire,s rare disease ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 With the ability ... HD resolution for more than 15 minutes, Fastec Imaging has ... world of high speed imaging. “Finally, a high speed camera ... we use in our everyday lives.” proclaims Matt Kearney, VP ... has always been to demystify and simplify the traditionally complicated ...
Breaking Biology Technology:Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3
... AVIV, Israel, September 23 InspireMD, Ltd.,announced today ... its study of,MGuard(TM) coronary stent in acute myocardial ... Study) is designed to evaluate,the safety and efficacy ... infarction. The first 3 patients were implanted,successfully with ...
... Affitech AS, the Norwegian human,antibody therapeutics company, ... milestone in its research and licensing collaboration ... against an unnamed oncology,target. Affitech has successfully ... that included its proprietary antibody library and ...
... KNDL ), a,leading, global full-service clinical research ... Kendle, PharmD, will,participate in the annual UBS Global ... the Grand Hyatt New York, Park Avenue at ... presentation is,scheduled for Wednesday, September 24 at 9:30 ...
Cached Biology Technology:InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results 2InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results 3Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration 2
(Date:7/23/2014)... A 2C increase in temperature around the world by ... the Intergovernmental Panel on Climate Change (IPCC), may be ... processes involved in the growth of forage plants such ... for livestock grazing in tropical countries such as Brazil., ... researchers in the Department of Biology at the Ribeiro ...
(Date:7/23/2014)... will play an increasingly important role in carbon and ... zones expand, according to research published this week in ... . , University of British Columbia researchers plumbed the ... to chart how microbial community metabolism changes as oxygen ... detailed picture of how SUP05 a bacterial group ...
(Date:7/23/2014)... will publish the International Journal of Fuzzy Systems ... Taiwan Fuzzy Systems Association (TFSA). The cooperation will allow ... area of fuzzy research., The International Journal of ... that deal with the theory, design and application of ... theory systems ranging from hardware to software. Launched in ...
Breaking Biology News(10 mins):An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
... an advance that could help ease the antibiotic drought, ... test that enlists pinhead-sized worms in efforts to discover ... ACS Chemical Biology , a monthly journal. ... that existing methods for identifying germ-fighting drugs involve adding ...
... diplomats and campaigners prepare to attend the COP15 conference ... battle against climate change in one of the most ... increasingly complex territory of climate negotiations is being revealed ... IOP Publishing,s Environmental Research Letters . ...
... A compound initially isolated from a soft coral ( Capnella ... scientists to develop a new set of treatments for neuropathic ... nervous system. Currently this form of pain is very ... or even opioids like morphine) and novel treatments are urgently ...
Cached Biology News:Climate change poker: The barriers which are preventing a global agreement 2Neuropathic pain: The sea provides a new hope of relief 2
... 19 x 29 cm, 1. One ... staining of Coomassie Blue or silver-stain gels ... blots for high sensitivity ECL detection and ... volume, and processing time.Proven design for consistent, ...
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
... Plus Western Blotting Reagent Pack, 1. ... detection of membrane-bound mouse and rabbit primary ... PVDF membranes. Detection reagents are not included, ... with ECL Plus. Category: Blotting & ...
... FHS-LVF and CVD-Diffuse We've combined our ... to create the world's first notch filter ... bandpass. Each filter features an excellent transmission ... These filters -- with interference coatings applied ...
Biology Products: